ONO and Report Submission of sBLA for Opdivo (nivolumab) + Yervoy (ipilimumab) as 1L Treatment of Unresectable Advanced or Recurrent ESCC in Japan
Shots:
- The application is based on P-III CheckMate -648 study evaluating Opdivo (3mg/kg- q2w- IV) + Yervoy (1mg/kg- q6w up to 24mos.) or Opdivo + CT vs CT alone in patients with unresectable advanced or recurrent ESCC
- The results demonstrated an improvement in OS at pre-specified interim analysis in patients with tumor cell PD-L1 expression ≥1% & all-randomized population with both combination therapy. The safety profiles were consistent with the known safety profiles of the individual components
- ONO also submitted an sBLA of Opdivo + CT for the same indication. In the 2011 agreement- BMS got territorial rights from Ono to develop & commercialize Opdivo globally (Ex-Japan- South Korea & Taiwan)
Ref: Ono Pharma | Image: BMS
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com